Janssen/Legend’s Cilta-Cel Consistent In Earlier Myeloma, Longer-Term Results

Bristol’s Abecma Beat CAR-T To Market, Maybe Not In Second-Line

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.